bioMérieux trims medium-term targets after mixed H1 results, shares dip
bioMérieux shares fell after the company reported first-half 2026 results and revised down its medium-term targets for 2027 and 2028, citing a changed geopolitical and macroeconomic backdrop. Management reduced its annual organic revenue growth ambition to 3%–6% for those years and lowered CEBIT growth expectations, a development that eclipsed othe…